WO2003037315A1

WO2003037315A1 - Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity

Info

Publication number: WO2003037315A1
Application number: PCT/KR2002/002031
Authority: WO
Inventors: Min-Young Kim; Byung-Young Park; Kyoung-Mi Kim; Nack-Do Sung; Pyung-Keun Myung
Original assignee: Angiolab Inc.
Priority date: 2001-11-01
Filing date: 2002-10-31
Publication date: 2003-05-08
Also published as: KR20030036993A; KR100567125B1; EP1450777A1; US20040209952A1; ES2422891T3; EP1450777A4; US7572831B2; EP1450777B1

Abstract

The present invention provides an MMP-inhibitory composition comprising chalcone or its derivatives. They inhibit the MMPs in collagenase subfamily as well as those in gelatinase subfamily. The MMP inhibitory activity of chalcone derivatives was similar to or greater than that of parent compound, chalcone. Chalcone or its derivatives of the present invention inhibit activity of matrix metalloproteinase, so that it can be applied to treat and prevent diseases related to matrix metalloproteinase.

Description

PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY

FIELD OF INVENTION

The present invention relates to a pharmaceutical composition comprising chalcone or its derivatives having matrix metalloproteinase inhibitory activity. This particular composition comprising chalcone or its derivatives inhibits matrix metalloproteinase activity.

BACKGROUND OF THE INVENTION

Chalcones (or chalcone derivatives) are compounds having the basic C6-C3- C6 arrangement in which middle three carbon atoms do not form a closed ring. These are important precursors in the synthesis of pigment in plant. Since they have anti- oxidant effect, they can do protective action from the harmful UV irradiation (Woo W.S.; Methodology of natural product chemistry (Seoul National University Publishing), ppl31-137). These compounds are abundant in the plant of the genus Corepsis. Chalcones in natural origin including 2'6'-dihydroxy-4-methoxychalcone, carthamin, and butein are identified from plants such as cinnamon, red pepper and carthamus flower. Dihydrochalcone is contained in certain species of the genus Rosaceae and Rhododendron, and phloridzin is one of the components in apple tree foliage (Hunter, M.D.; Phytochemistry (Oxford) 34, ppl251-1254, 1993). Chalcones are known as inhibitors for glucose transport and growth of various cells including cancer, which enables to apply them in the prevention from aging and/or cancer (Fuhrmann, G.F., Dernedde, S. and Frenking G.; Biochimica Biophysica Acta, 1110. ppl05-lll, 1992; Kobor, M., et al; Cancer Lett., 119. pp207-212, 1997; Calliste, C.A., et al; Anticancer Res., 21, pp3949-3956, 2001).

Matrix metalloproteinases (MMPs), a family of over 20 proteins are endopeptidase, which degrade or proteolyze the components of the extracellular matrix such as collagen, proteoglycan, and gelatin. They are classified into four groups: collagenase, gelatinase, stromelysin, and membrane-type MMP.

Collagenase proteolyzes the triple helix interstitial collagen and gelatin, and it comprises interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8) and collagenase-3 (MMP- 13). These three enzymes share more than 50% sequence similarity, having two zinc-binding sites and one or two calcium binding sites in their core domain (Borkakoti et al.; Nature Struct. Bioi, 1, pp 106- 110, 1994; Bode, et al.; EMBO J., 13, ppl263-1269, 1994; Lovejoy et al; Science, 263, pp375-377, 1994).

Gelatinase can degrade denatured collagen and type IV, N VII and X collagen. There are two gelatinases, one is 72 kDa gelatinase-A (MMP-2) secreted from fibroblast, and the other is 92 kDa gelatinase B (MMP-9) secreted from mononuclear phagocytes. They specifically act on type IV collagen, the major component of the basement membrane (Murphy, G. et al; Biochem. J., 258, pp463-472, 1989; Stetler- Stevenson, W. G. et al.; J. Biol. Chem., 264, ppl353-1356, 1989). These enzymes are very important in cancer invasion and metastasis. As compared with MMP-2, MMP-9 comprises additional sequences with unknown functions between the C-terminal and catalytic domain (Wilhelm, S. M. et al; J. Biol. Chem., 264, ppl7213-17221, 1989).

Stromelysins show a broad substrate spectrum and stromelysin- 1 (MMP-3), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11), and matrilysin (MMP-7) are classified as stromelysins (Chin, J. R. et al; J. Biol. Chem., 260. ppl2367-12376, 1985; Whitham, S. E. et al; Biochem. J., 240, pp913-916, 1986).

Metalloelastinase (MMP- 12) and membrane-type MMP such as MT1-MMP (MMP-14), MT2-MMP (MMP-15) and MT3-MMP (MMP-16), are also identified as enzymes in the MMP family.

Many enzymes in the MMP family have substrate specificity. The expression of MMP is induced under various physiological circumstances when remodeling of an extracellular matrix is required (Curry, T.E. Jr., Osteen, K.G.; Biol. Repord., 64, ppl285-1296, 2001; Damjanovske, S., et al; Ann. NY Acad. Sci., 926, pρl80-191,

2000; Ravanti L, Kahari VM; Int. J. Mol. Med., 6, pp391-407, 2000).

Increased expression or activation of MMPs is observed in many pathological states, such as atherosclerosis, restenosis, MMP-dependent-osteopathy, inflammation of the central nervous system, Alzheimer's disease, asthma, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, osteoporosis, endometriosis, corneal ulcer synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, multiple sclerosis, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane ruptures, inflammatory bowel disease, gingivitis, periodontal disease, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature retinopathy, eye inflammation, corneal ulceration, Sjogren's syndrome, myopia, eyes tumors, rejection of cornea implantation, angiogenesis and cancer metastasis (Woessner Jr.; Ann. NY Acad. Sci., 732, ppll-21, 1994; Warner et al; Am. J. Pathol, 158, pp2139-44, 2001; Stetler-Stevenson; Surg. Oncol. Clin. N. Am., 10, pp383-92, 2001). For example, stromelysins are known to be the major enzyme for disruption of cartilage (Murphy, G. et al; Biochem. J., 248, pp265-268, 1987). Collagenases, gelatinases and stromelysins are responsible for the degradation of the extracellular matrix in many retinopathies (Brans, F.R. et al; Invest. Opthalmol. and Visual Sci., 32, ppl569-1575, 1989). Collagenases and stromelysins are identified in fibroblast from gingiva in inflammation and the activity of the enzyme is dependent on the degree of inflammation (Overall, CM. et al; J. Periodontal Res., 22, pp81-88, 1987). MMP activity is highly enhanced in response to the bacterial infection and inflammation in gingival crevicular fluid taken from patients with periodontal disease. Destruction of collagen in the periodontal matrix by MMP leads to gingival recession, pocket formation and tooth movement (Goulb, LB., Ryan M.E. Williams R.C.; Dent. Today, 17, pp 102- 109). Recent reports have also shown that MMP-1 activity is highly induced in

Alzheimer's disease, and MMP-1 and MMP-3 are involved in the pathophysiology of the disease (Leake A, et al; J. Neurosci. Lett., 291, pp201-3, 2000; Yoshiyama Y, et al; Acta Neuropathol (Berl), 99, ρρ91-5, 2000).

It is also found that MMP-9 is the major MMP in bronchoalveolar lavage fluid and bronchial mucosa in asthma and MMP-2 and MMP-9 are crucial for the induction of bronchial asthma (Mautina et al; J. Allergy Cli.n Immunol, 104, pp530- 533, 1999; Kumagai et al; J. Immunol, 162, pp4212-4219, 1999; Bechy Kelly et al; Am JRespir Crit Care Med, 162, ppll57-1161, 2000).

MMPs are also responsible in solar UN radiation-induced skin damage, affecting skin tone and resiliency leading to premature aging. The symptoms of which include leathery texture, wrinkles, mottled pigmentation and laxity. Therefore, MMP inhibitors could be included in cosmetics for anti-photoaging or anti-wrinkle treatment (Hase T et al; Br. J. Dermatol, 142, pp267-273, 2000; Fisher GJ; Photochem. Photobiol, 69, ppl54-157, 1999). Since MMP inhibitors can be applied to the treatment and prevention of many diseases, development of MMP inhibitors as new therapeutics is expected. These inhibitors need to be administered for a long time, so that desirable inhibitors should not have toxic or adverse effect with good patient compliance. DISCLOSURE OF THE INVENTION

Accordingly, it is an object of the present invention to provide a pharmaceutical composition comprising chalcone or its derivatives having matrix metalloproteinase (MMP) inhibitory activity.

Chalcone or its derivatives according to the present invention are shown in formula (I);

Wherein R, to Rio is H, OH, OCH₃ or Cl, respectively.

In accordance with an aspect of the present invention, there is also provided, preferably, chalcone and an inventive chalcone derivatives such as phloretin(4- hydroxy, 2'4'6'-trihydroxy chalcone), phloridzin, dihydrochalcone, 2',6'-dihydro-4'- methoxychalcone, 2-hydroxychalcone, 4-hydroxychalcone, 4'-hydroxychalcone, 4- methoxychalcone, 4 '-methoxychalcone, 2', 4'-dimethoxychalcone, carthamine, butein and its mixture, most preferably, chalcone, phloretin, 2-hydroxychalcone, 4- hydroxychalcone, 4-methoxychalcone, 4 '-methoxychalcone and 2', 4'- dimethoxychalcone.

In accordance with an aspect of the present invention, there is also provided a pharmaceutical composition to inhibit the activity of MMP such as MMP-1, MMP-2, MMP-9 and MMP-13.

It is an another object of the present invention to provide a pharmaceutical composition comprising chalcone or its derivatives for prevention and treatment of MMP-dependent diseases such as atherosclerosis, restenosis, MMP-dependent osteopathy, inflammation of central nervous system, Alzheimer's disease, asthma, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, osteoporosis, endometriosis, comeal ulcer synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, multiple sclerosis, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane rapture, inflammatory bowel disease, gingivitis, periodontal disease, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature retinopathy, eye inflammation, comeal ulceration, Sjogren's syndrome, myopia eye tumor, rejection of cornea implantation, angiogenesis, infiltration and cancer metastasis.

It is still another object of the present invention to provide a use of chalcone or its derivatives for the preparation of a pharmaceutical composition to treat and prevent MMP-dependent diseases caused by abnormal MMP activity. It is still another object of the present invention to provide a method of treating

MMP-dependent diseases such as atherosclerosis, restenosis, MMP-dependent osteopathy, inflammation of central nervous system, Alzheimer's disease, asthma, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, osteoporosis, endometriosis, comeal ulcer synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, multiple sclerosis, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane rapture, inflammatory bowel disease, gingivitis, periodontal disease, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature retinopathy, eye inflammation, comeal ulceration, Sjogren's syndrome, myopia eye tumor, rejection of cornea implantation, angiogenesis, infiltration and cancer metastasis with an effective amount of pharmaceutical composition according to the present invention. Hereinafter, the present invention will be explained in detail. The inventors recognize the inhibitory effect of chalcone or its derivatives on matrix metalloproteinase activity. Therefore, the present invention provides a chalcone or its derivatives for prevention and treatment of MMP-dependent diseases. Chalcone or its derivatives of the present invention can be purchased or synthesized with conventional methods.

An inventive chalcone or its derivatives may be prepared in accordance with the following preferred embodiment.

Benzaldehyde, substituted benzaldehyde, acetophenone or substituted acetophenone and sodium hydroxide are suspended in organic solvent and stirred at a temperature ranging from -20 to 50°C, preferably from 10 to 30°C, for a period ranging from 1 to 24 hours, preferably 3 to 10 hours. And then the mixture is neutralized with acid such as hydrochloric acid and extracted with ethylacetate. The extracted organic phase is removed under vaccum, followed by purification with silica gel column chromatography (eluant: n-hexane and ethylacetate mixture).

Above substituted benzaldehydes is selected from the group consisting of 2- hydroxybenzaldehyde, 4-hydroxybenzaldehyde and the like, and substituted acetophenone is selected from the group consisting of 4-methoxyacetophenone, 2,4- dimethoxyacetophenone and the like. Organic solvent is selected from the group consisting of methanol, ethanol, ethylacetate, acetone, ether and the like.

When the effect of chalcone or its derivatives on MMPs was investigated with MMP-1, MMP-2, MMP-9 and MMP-13, it drastically inhibited activity of all four enzymes. The inhibitory effect of chalcone and its derivatives on MMPs is not, however, limited to these enzymes. In accordance with an aspect of the present invention, there is also provided a anti-angiogenic composition comprising chalcone or its derivatives of the present invention for inhibiting MMP activity In accordance with another aspect of the present invention, there is also provided a pharmaceutical composition comprising chalcone or its derivatives of the present invention as an active ingredient for prevention and treatment of MMP- dependent diseases. The pharmaceutical composition of this invention may be used with more than one other composition. Preparation comprising chalcone or its derivatives can contain about 0J-80w/w%, preferably l-30w/w% chalcone or its derivatives as active ingredients. Topical formulation of the chalcone or its derivatives includes cream, lotion, ointment, aerosol, spray and paste. Desirable composition of the chalcone or its derivatives in the topical formulation is 0.001 -20%, preferably 0.05-10%.

Accordingly, the present invention also provides a pharmaceutical composition for prevention and treatment of MMP-dependent diseases, which comprises chalcone or its derivatives as an active ingredient, in combination with pharmaceutically acceptable excipients, carriers or diluents. Pharmaceutical composition can be comprised in pharmaceutically acceptable diluent such as saline, buffered saline, dextrose, water, glycerol, ethanol and the mixture thereof, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).

A pharmaceutical formulation may be prepared by using the composition in accordance with any of the conventional procedures. In preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier or enclosed within a carrier, which may be in the form of a capsule, sachet or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient. Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoates, propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.

Pharmaceutical formulations containing chalcone or its derivatives may be prepared in any form, such as oral dosage form (tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).

The pharmaceutical formulations comprising chalcone or its derivatives of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous, infraperitoneal, intramuscular, intra-arterial, rectal, nasal, ocular, and topical introduction. A daily dose of a chalcone or its derivatives is preferable from about 5 mg to 2 g, most preferably 10 to 1000 mg. In general, 0J to 200 rag/kg of chalcone or its derivatives can be administrated in a single dose or 2-3 divided doses per day. Inventive pharmaceutical composition may be applied differently according to the purpose of dosing and diseases. It should be understood that the amount of active ingredient has to be determined with various factors. These factors include the severity of the patient's symptoms, other co-administrated drugs (e.g., chemotherapeutic agents), age, sex, body weight of the individual patient, food, dosing time, the chosen route of administration, and the ratio of the composition.

Therefore, the above dose should not be intended to further illustrate the present invention without limiting its scope. BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which:

Fig. 1 is a graph showing the inhibition of MMP-1 by chalcone;

Fig. 2 is a graph showing the inhibition of MMP-9 by chalcone;

Fig. 3 is a picture showing tube formation of HUVEC treated with 0.5% DMSO; Fig. 4 is a picture showing tube formation of HUVEC treated with chalcone;

Fig. 5 is a picture showing tube formation of HUVEC treated with 4'- methoxychalcone.

BEST MODE FOR CARPJNG OUT THE INVENTION

The following examples are intended to further illustrate the present invention. However, these examples are shown only for better understanding the present invention without limiting its scope.

Example 1 ; Synthesis of 4-methoxychalcone (l-phenyl-3-(4- methoxyphenyl)prophenone)

Acetophenone (0.5 g) and sodium hydroxide (0J7 g) were suspended in 15 mi of methanol pre-chilled at -10°C. -Anisaldehyde (0.57 g) was added thereto, and stirred for 10 hr at room temperature. After neutralization with 5% hydrochloric acid solution, the product was extracted with 100 ml of ethylacetate. The extracted organic phase was dried with anhydrous magnesium sulfate, and concentrated under vacuum evaporator. Purified compound was obtained by elution with n- hexane:ethylacetate (v/v, 1:7) through silica gel column chromatography (5 x 3 cm, Merk), and identified as follows; m.p.=68 ~70^°C,

Η-NMR (CDC1₃ /TMS)δ (ppm) : 3.85(s, 3H), 6.9~7.0(d, 2H), 7.4~7.6(m, 6H), 7.7 ~ 7.8(d, 1H), 7.9 ~ 8.0(m, 2H)

Example 2 : Synthesis of 2-hydroxychalcone (l-phenyl-3-(2- hydiOxyphenyl)prophenone)

2-Hydorxybenzaldehyde (2 g) and sodium hydroxide (0.72 g) were dissolved in 30 mi of anhydrous toluene and refluxed for 3 hrs. The resulting salt was filtered with glass filter and completely dried. The preformed salt (2 g) and mefhoxymethyl chloride (1.29 g) were suspended in 30 mi of anhydrous toluene and then st red for 5 hrs. The product extracted with 100 mi of ethylacetate was dried with anhydrous magnesium sulfate, and concentrated under vacuum evaporator. The product was 2.5 g of colorless liquid phase of 2-methoxymethyl-oxybenzaldehyde.

The previous product was mixed with acetophenone (2 g) suspended in methanol at -10°C and stirred for 5 hr at room temperature. After neutralization with 5% hydrochloric acid solution, the product was extracted with 200 mi of ethylacetate. The extracted organic phase was dried with anhydrous magnesium sulfate, and resulting l-phenyl-3-(2-methoxymethyloxyphenyl)- prophenone was hydrolyzed with dilute alkaline solution. The reaction mixture was extracted with 200 ml of ethylacetate. Extracted organic phase is dried with anhydrous magnesium sulfate and evaporated under vacuum. About 0.9 g of white solid was obtained and subjected to silica gel column chromatography (5 x 3 cm, Merk). After being eluted with n- hexane: ethylacetate (v/v, 1:7), 0.7 g of purified compound was recovered and identified as follows; m.p.=148 ~ 149^°C, 1H-NMR (CDC1₃ /TMS)δ (ppm) : 6.6~6.8(m, 2H), 6.9~7.05(t, IH), 7.2~7.4(m, 5H), 7.4~7.6(d, IH), 7.7~7.8(m, 2H), 9.4(s, IH); Mass (m/z, relative intensity) : 225(5, M+), 77(100)

Example 3 : Synthesis of 4-hydroxychalcone (l-phenyl-3-(4- hydroxyphenyl)prophenone)

This compound was prepared with 4-hydroxybenzaldehyde followed by same procedure as previously mentioned in Example 2. The purified compound (0.7 g) was identified as follows; m.p.=182~ 183 ^°C ,

Η-NMR (CDC1₃ /TMS)δ (ppm) : 3.5(s, IH), 6.9(d, 2H), 7.5 ~7.7(m, 5H), 7.7~7.8(d, IH), 8.0~ 8J(m, 2H); Mass (m/z), relative intensity) : 225(55, M+), 77(100)

Example 4 : Synthesis of 4 '-methoxychalcone (l-(4-methoxyphenyl)-3- phenylprophenone)

4-Methoxyacetophenone (1.4 g) and sodium hydroxide (0.2 g) were suspended in 15 mi of methanol pre-chilled at -10°C. The solution was kept for 1 hr under

0°C with stirring. Benzaldehyde (1 g) was added thereto, and refluxed for 10 hr at room temperature with stirring. After neutralization with 5% hydrochloric acid solution, the product was extracted with 100 mi of ethylacetate. The extracted organic phase was dried with anhydrous magnesium sulfate, and evaporated under vacuum. The resulting 1.3 g of white powder was purified through silica gel column chromatography (5 x 3 cm, Merk), which is eluted with n- hexane: ethylacetate (v/v, 1 :7). The purified compound was identified as follows; m.p.=98 ~ 100^°C,

1H-NMR (CDC1₃ /TMS)δ (ppm) : 3.85 ~3.9(s, 3H), 6.95 ~7.05(d, 2H), 7.4~7.45(m, 3H), 7.5 ~7.6(d, IH), 7.6~7.7(m, 2H), 7.75 ~7.85(d, IH), 8.0~8.1(m, 2H); Mass (m/z, relative intensity) :239(14, M+), 77(100)

Example 5 : Synthesis of 2',4'-dimethoxychalcone (l-(2,4-dimethoxyphenyl)-3- phenylprophenone)

It was prepared with 2,4-dimethoxybenzaldehyde followed by same procedure as previously mentioned in Example 4. The purified compound was identified as follows; 1H-NMR (CDCl₃/TMS)δ (ppm) :3.8 ~3.95(m, 6H), 6.45 ~6.6(m, 2H),

7.3 ~7.4(m, 4H), 7.5 ~7.65(m, 3H), 7.7~7.8(m, 2H); Mass (m/z, relative intensity) : 269(9, M+), 165(100)

Experimental Example 1 : Effect of Chalcone derivatives on Matrix Metalloproteinase activity

(1) Preparation of MMP

MMP-1, MMP-2, MMP-9 and MMP-13 were cloned and prepared from insect cells (Sf21 insect cell) by using a Baculo virus system. Each cDNA for coπesponding MMPs was cloned to a pBlueBac4.5 transfer vector (Invitrogen, Cat no. VI 995-20), and then transfected to Sf21 cells with a Bac- N-Blue Transfection Kit (Invitrogen, Cat no. K855-01). Sf21 cells were incubated with a TNM-FH (Sigma, St. Louis, MO, U.S. A) media containing 10% fetal bovine serum at 27 °C, then harvested and re-suspended at a concentration of 10⁷ cell/m£. The cell suspension was incubated with a viras containing the cloned gene for 1 hr at room temperature. Infected Sf21 cells were grown for 72 hrs and the medium was recovered, and the MMP was purified. MMP-2 (GENEBANK No. XM_048244) and MMP-9 (GENEBANK No. XM_009491) were recovered from a gelatin-sepharose affinity column (Sigma, G5384) by eluting with 5% DMSO-containing buffer. MMP-1 (GENEBANK NO. XM_040735) and MMP-13 (GENEBANK NO. NM_002427) were purified with SP-sepharose column (Pharmacia, 17-02729-01) chromatography.

(2) Inhibition of MMP activity

In order to investigate MMP inhibition by chalcone or its derivatives, MMP enzyme activity was assayed by a spectrofluorometric method using Perkin-Elmer LS50B. Purified MMP-1, MMP-2, MMP-9 and MMP-13 were used after activation with 1 mM APMA before assay.

The substrate for MMP-1 was 2,4-dinitrophenyl-Pro-Leu-Ala-Leu-Trp-Ala- Arg-OH (Calbiochem), and 2,4-dinitrophenyl-Pro-Leu-Met-Trp-Ser-Arg-OH (Calbiochem) was used for MMP-2 and MMP-9 activity assay. As a substrate for MMP-13, MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH₂ (Calbiochem) was used [MCA=methyl coumarylamide; Cha= L-cyclohexylalanine; Nva= L-norvaline; Dpa=3-(2,4-dinitrophenyl)-L-2,3-diaminoproprionic acid].

As a control, 2 mi of reaction buffer (50 mM Tricine, pH 7.5, 10 mM CaCl₂, 200 mM NaCl) comprising DMSO, 10 nM of enzyme and 10 μM of substrate was prepared in a cuvette. Fluorescence intensity was measured for 5-10 min at room temperature with a spectrofluorometer.

Chalcone or its derivatives were added to a reaction buffer containing a substrate and enzyme, and fluorescence intensity was measured as the same manner.

Figures 1 and 2 are diagrams of activity of MMP-1 and MMP-9. As shown in figures, about 75% of MMP-1 and 76% of MMP-9 activity were inhibited by chalcone.

Chalcone also inhibits activity of MMP-2 and MMP-13 by about 80%. The extent of

MMP inhibition by each derivative was similar to or greater than that by parent compound, chalcone. The results for MMP-2 and MMP-13 inhibition are summarized in Table 1.

[Table 1] MMP Inhibitory activity of chalcone or its derivatives

Experimental Example 2 : Effect of chalcone or its derivatives on tube formation of

HUVEC

The effect of chalcone or its derivatives on human endothelial cells was investigated to evaluate the biological effect of chalcones as MMP inhibitors. Since

MMPs are responsible for the degradation of extracellular matrix, chalcone or its derivatives can inhibit the formation of tubular network of vessel, which represent migration and differentiation of endothelial cell.

Blood vessel endothelial cells, human umbilical vein endothelial cells (HUVECs), were isolated from freshly obtained cords after cesarean section according to Grants' method (Grants D.S., et al, Cell, 58, pp933-943, 1989). They were identified by immunocytochemical staining with anti-Factor VIII antibody.

HUVECs cultured on Matrigel (BD Bioscience, Bedford, MA, USA) were treated with 50 μM of chalcone or its derivatives, and further incubated at 37 ^°C for 8-16 hrs. As a control, the procedure was repeated with the solvent of the above compounds.

Fig. 3 shows that a tubular network is formed as a process of neovascularization, when they are grown on Matrigel. However, the microvascular network was disconnected when HUVECs grown on Matrigel were treated with 50 μM of chalcone (Fig. 4) or 4'-methoxy chalcone (Fig. 5). These data show that chalcone and its derivatives can inhibit angiogenesis by inhibiting MMP activity.

INDUSTRIAL APPLICABILITY

As previously mentioned, chalcone or its derivatives of the present invention inhibits matrix metalloproteinase activity. Based on that, chalcone and its derivatives can be used as a new drug for treatment and prevention of MMP-dependent diseases.

Claims

1. A pharmaceutical composition comprising compound of formula (I) having matrix metalloproteinase (MMP) inhibitory activity and a pharmaceutically acceptable diluent or carrier;

wherein

Ri to Rio is H, OH, OCH₃ or Cl, respectively

2. The pharmaceutical composition of claim 1, wherein said compound is selected from the group consisting of chalcone, phloretin (4-hydroxy, 2',4',6'Jri hydroxy chalcone), 2-hydroxychalcone, 4-hydroxychalcone, 4-methoxychalcone, 4'- methoxychalcone and 2', 4'-dimethoxychalcone.

3. The pharmaceutical composition of claim 1, wherein said matrix metalloproteinase is selected from MMP-1, MMP-2, MMP-9 and MMP-13.

4. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is used for treatment and prevention of diseases caused by abnormal MMP activity.

5. The pharmaceutical composition of claim 4, wherein said disease is selected at least one from the group consisting of atherosclerosis, restenosis, MMP-dependent osteopathy, inflammation of central nervous system, Alzheimer's disease, asthma, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, osteoporosis, endometriosis, comeal ulcer synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, multiple sclerosis, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane rapture, inflammatory bowel disease, gingivitis, periodontal disease, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature retinopathy, eye inflammation, comeal ulceration, Sjogren's syndrome, myopia eye tumor, rejection of cornea implantation, angiogenesis, infiltration and cancer metastasis.

6. Use of the composition of claims 1 or 2 for the preparation of pharmaceutical composition for the treatment and prevention of diseases caused by abnormal MMP activity.